![]() |
|||||||
|
Fusion Protein:ZNF738-DAPK1 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: ZNF738-DAPK1 | FusionPDB ID: 102858 | FusionGDB2.0 ID: 102858 | Hgene | Tgene | Gene symbol | ZNF738 | DAPK1 | Gene ID | 148203 | 1612 |
Gene name | zinc finger protein 738 | death associated protein kinase 1 | |
Synonyms | - | DAPK|ROCO3 | |
Cytomap | 19p12 | 9q21.33 | |
Type of gene | protein-coding | protein-coding | |
Description | protein ZNF738 | death-associated protein kinase 1DAP kinase 1 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | P53355 Main function of 5'-partner protein: FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing stress fiber formation in endothelial cells. Phosphorylates STX1A and significantly decreases its binding to STXBP1. Phosphorylates PRKD1 and regulates JNK signaling by binding and activating PRKD1 under oxidative stress. Phosphorylates BECN1, reducing its interaction with BCL2 and BCL2L1 and promoting the induction of autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating mTORC1 activity in a growth factor-dependent pathway. Phosphorylates RPS6, MYL9 and DAPK3. Acts as a signaling amplifier of NMDA receptors at extrasynaptic sites for mediating brain damage in stroke. Cerebral ischemia recruits DAPK1 into the NMDA receptor complex and it phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx through NMDA receptor channels, resulting in an irreversible neuronal death. Required together with DAPK3 for phosphorylation of RPL13A upon interferon-gamma activation which is causing RPL13A involvement in transcript-selective translation inhibition.; FUNCTION: Isoform 2 cannot induce apoptosis but can induce membrane blebbing. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000311015, ENST00000380870, ENST00000597810, ENST00000594245, | ENST00000466188, ENST00000491893, ENST00000358077, ENST00000408954, ENST00000469640, ENST00000472284, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 7 X 5 X 5=175 | 9 X 8 X 6=432 |
# samples | 7 | 9 | |
** MAII score | log2(7/175*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/432*10)=-2.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: ZNF738 [Title/Abstract] AND DAPK1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: ZNF738 [Title/Abstract] AND DAPK1 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ZNF738(21558766)-DAPK1(90311922), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | ZNF738-DAPK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF738-DAPK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF738-DAPK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF738-DAPK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | DAPK1 | GO:0006468 | protein phosphorylation | 10629061 |
Tgene | DAPK1 | GO:0017148 | negative regulation of translation | 18995835 |
Tgene | DAPK1 | GO:0035556 | intracellular signal transduction | 10629061 |
Tgene | DAPK1 | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 16132846 |
Tgene | DAPK1 | GO:0046777 | protein autophosphorylation | 10629061|12730201 |
Tgene | DAPK1 | GO:0071346 | cellular response to interferon-gamma | 18995835 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:21558766/chr9:90311922) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000311015 | ZNF738 | chr19 | 21558766 | + | ENST00000358077 | DAPK1 | chr9 | 90311922 | + | 3677 | 530 | 19 | 2409 | 796 |
ENST00000311015 | ZNF738 | chr19 | 21558766 | + | ENST00000472284 | DAPK1 | chr9 | 90311922 | + | 3676 | 530 | 19 | 2409 | 796 |
ENST00000311015 | ZNF738 | chr19 | 21558766 | + | ENST00000469640 | DAPK1 | chr9 | 90311922 | + | 3754 | 530 | 19 | 2484 | 821 |
ENST00000311015 | ZNF738 | chr19 | 21558766 | + | ENST00000408954 | DAPK1 | chr9 | 90311922 | + | 3674 | 530 | 19 | 2409 | 796 |
ENST00000380870 | ZNF738 | chr19 | 21558766 | + | ENST00000358077 | DAPK1 | chr9 | 90311922 | + | 3615 | 468 | 149 | 2347 | 732 |
ENST00000380870 | ZNF738 | chr19 | 21558766 | + | ENST00000472284 | DAPK1 | chr9 | 90311922 | + | 3614 | 468 | 149 | 2347 | 732 |
ENST00000380870 | ZNF738 | chr19 | 21558766 | + | ENST00000469640 | DAPK1 | chr9 | 90311922 | + | 3692 | 468 | 149 | 2422 | 757 |
ENST00000380870 | ZNF738 | chr19 | 21558766 | + | ENST00000408954 | DAPK1 | chr9 | 90311922 | + | 3612 | 468 | 149 | 2347 | 732 |
ENST00000597810 | ZNF738 | chr19 | 21558766 | + | ENST00000358077 | DAPK1 | chr9 | 90311922 | + | 3596 | 449 | 130 | 2328 | 732 |
ENST00000597810 | ZNF738 | chr19 | 21558766 | + | ENST00000472284 | DAPK1 | chr9 | 90311922 | + | 3595 | 449 | 130 | 2328 | 732 |
ENST00000597810 | ZNF738 | chr19 | 21558766 | + | ENST00000469640 | DAPK1 | chr9 | 90311922 | + | 3673 | 449 | 130 | 2403 | 757 |
ENST00000597810 | ZNF738 | chr19 | 21558766 | + | ENST00000408954 | DAPK1 | chr9 | 90311922 | + | 3593 | 449 | 130 | 2328 | 732 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000311015 | ENST00000358077 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001532163 | 0.99846786 |
ENST00000311015 | ENST00000472284 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001520842 | 0.9984792 |
ENST00000311015 | ENST00000469640 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001379185 | 0.99862087 |
ENST00000311015 | ENST00000408954 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001494591 | 0.9985055 |
ENST00000380870 | ENST00000358077 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001478447 | 0.9985216 |
ENST00000380870 | ENST00000472284 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001467583 | 0.9985324 |
ENST00000380870 | ENST00000469640 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001332162 | 0.99866784 |
ENST00000380870 | ENST00000408954 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001441403 | 0.9985586 |
ENST00000597810 | ENST00000358077 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001471762 | 0.99852824 |
ENST00000597810 | ENST00000472284 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001460487 | 0.99853957 |
ENST00000597810 | ENST00000469640 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001327545 | 0.9986725 |
ENST00000597810 | ENST00000408954 | ZNF738 | chr19 | 21558766 | + | DAPK1 | chr9 | 90311922 | + | 0.001428323 | 0.99857163 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for ZNF738-DAPK1 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
ZNF738 | chr19 | 21558766 | DAPK1 | chr9 | 90311922 | 449 | 106 | WNMKRHSMVATPPGVGDFSVWEFSGN |
ZNF738 | chr19 | 21558766 | DAPK1 | chr9 | 90311922 | 468 | 106 | WNMKRHSMVATPPGVGDFSVWEFSGN |
ZNF738 | chr19 | 21558766 | DAPK1 | chr9 | 90311922 | 530 | 170 | WNMKRHSMVATPPGVGDFSVWEFSGN |
Top |
Potential FusionNeoAntigen Information of ZNF738-DAPK1 in HLA I |
![]() |
ZNF738-DAPK1_21558766_90311922.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:22 | SMVATPPGV | 0.9925 | 0.6184 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:21 | SMVATPPGV | 0.9878 | 0.753 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:13 | SMVATPPGV | 0.9877 | 0.7863 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:67 | SMVATPPGV | 0.9876 | 0.6434 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:30 | SMVATPPGV | 0.9876 | 0.6434 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:11 | SMVATPPGV | 0.9876 | 0.6783 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:60 | SMVATPPGV | 0.9876 | 0.6111 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:24 | SMVATPPGV | 0.9876 | 0.6434 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:27 | SMVATPPGV | 0.9875 | 0.697 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:38 | SMVATPPGV | 0.9837 | 0.6896 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:35 | SMVATPPGV | 0.9806 | 0.6579 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:29 | SMVATPPGV | 0.9734 | 0.6428 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:04 | SMVATPPGV | 0.9703 | 0.8335 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:20 | SMVATPPGV | 0.9689 | 0.6525 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:19 | SMVATPPGV | 0.9592 | 0.5595 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:17 | SMVATPPGV | 0.9436 | 0.7269 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-B13:02 | SMVATPPGV | 0.0458 | 0.9294 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-B53:01 | PPGVGDFSVW | 0.8035 | 0.6905 | 11 | 21 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-B53:01 | TPPGVGDFSVW | 0.9871 | 0.6498 | 10 | 21 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:01 | SMVATPPGV | 0.9876 | 0.6434 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C01:17 | ATPPGVGDF | 0.0593 | 0.9189 | 9 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C01:30 | ATPPGVGDF | 0.0194 | 0.9052 | 9 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C03:07 | VATPPGVGDF | 0.997 | 0.9564 | 8 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:03 | SMVATPPGV | 0.9938 | 0.819 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:14 | SMVATPPGV | 0.9878 | 0.6911 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-A02:06 | SMVATPPGV | 0.9878 | 0.753 | 6 | 15 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C01:02 | ATPPGVGDF | 0.0658 | 0.9121 | 9 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C01:03 | ATPPGVGDF | 0.0242 | 0.849 | 9 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-C03:02 | VATPPGVGDF | 0.9989 | 0.9486 | 8 | 18 |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 | HLA-B53:02 | TPPGVGDFSVW | 0.9862 | 0.5971 | 10 | 21 |
Top |
Potential FusionNeoAntigen Information of ZNF738-DAPK1 in HLA II |
![]() |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of ZNF738-DAPK1 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
8835 | SMVATPPGVGDFSV | ZNF738 | DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 530 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ZNF738-DAPK1 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 8835 | SMVATPPGVGDFSV | -5.47913 | -5.67113 |
HLA-B14:02 | 3BVN | 8835 | SMVATPPGVGDFSV | -3.84443 | -4.60543 |
HLA-B52:01 | 3W39 | 8835 | SMVATPPGVGDFSV | -6.76995 | -6.96195 |
HLA-B52:01 | 3W39 | 8835 | SMVATPPGVGDFSV | -5.58751 | -6.34851 |
HLA-A11:01 | 4UQ2 | 8835 | SMVATPPGVGDFSV | -5.74663 | -6.50763 |
HLA-A11:01 | 4UQ2 | 8835 | SMVATPPGVGDFSV | -5.69582 | -5.88782 |
HLA-A24:02 | 5HGA | 8835 | SMVATPPGVGDFSV | -8.42283 | -9.18383 |
HLA-A24:02 | 5HGA | 8835 | SMVATPPGVGDFSV | -7.2103 | -7.4023 |
HLA-B27:05 | 6PYJ | 8835 | SMVATPPGVGDFSV | -7.69112 | -7.88312 |
HLA-B44:05 | 3DX8 | 8835 | SMVATPPGVGDFSV | -5.89348 | -6.08548 |
HLA-B44:05 | 3DX8 | 8835 | SMVATPPGVGDFSV | -3.81554 | -4.57654 |
HLA-A02:01 | 6TDR | 8835 | SMVATPPGVGDFSV | -3.68024 | -4.44124 |
Top |
Vaccine Design for the FusionNeoAntigens of ZNF738-DAPK1 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 10 | 21 | TPPGVGDFSVW | CACCCCCAGGAGTTGGCGATTTCAGCGTGTGGG |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 11 | 21 | PPGVGDFSVW | CCCCAGGAGTTGGCGATTTCAGCGTGTGGG |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 6 | 15 | SMVATPPGV | GTATGGTAGCCACACCCCCAGGAGTTG |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 8 | 18 | VATPPGVGDF | TAGCCACACCCCCAGGAGTTGGCGATTTCA |
ZNF738-DAPK1 | chr19 | 21558766 | chr9 | 90311922 | 9 | 18 | ATPPGVGDF | CCACACCCCCAGGAGTTGGCGATTTCA |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of ZNF738-DAPK1 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
BRCA | ZNF738-DAPK1 | chr19 | 21558766 | ENST00000311015 | chr9 | 90311922 | ENST00000358077 | TCGA-E2-A1LG-01A |
Top |
Potential target of CAR-T therapy development for ZNF738-DAPK1 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to ZNF738-DAPK1 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ZNF738-DAPK1 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |